PREVIOUS
✖
GLP-1 Drugs
September 21 , 2025
14 hrs 0 min
20
0
- The WHO has added GLP-1 receptor agonists to its 24th Model List of Essential Medicines (EML) for type 2 diabetes.
- The addition includes semaglutide, dulaglutide, liraglutide, and tirzepatide.
- These drugs are indicated for adults with type 2 diabetes and associated cardiovascular disease, chronic kidney disease, or obesity.
- Globally, over 800 million people live with diabetes, with nearly half untreated.
- More than one billion people worldwide suffer from obesity, with rising rates in low- and middle-income countries.
- GLP-1 receptor agonists help lower blood glucose and support weight reduction.
- Listing on the EML aims to improve the affordability and accessibility of these medicines.
- The WHO updates the Model List of Essential Medicines every two years to address new health challenges and improve drug access.
Leave a Reply
Your Comment is awaiting moderation.